MedTrace Logo

RZL-012 for Dercum's Disease Lipomas

NCT04229030 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-02-07

Study results available
· View outcomes & findings →

Summary

Thirty-eight (38) subjects will be included in the study. Subjects will be randomized in a ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be enrolled in 3 clinical sites.

Conditions

  • Dercum's Disease Lipomas

Interventions

DRUG

RZL-012

small synthetic molecule for the treatment of Dercum's Disease lipomas

DRUG

Vehicle

Vehicle of RZL-012 drug product

Sponsors & Collaborators

  • Raziel Therapeutics Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-30
Primary Completion
2021-02-20
Completion
2021-02-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04229030 on ClinicalTrials.gov